Previous evidences showed that several methylation‐related gene mutations including ASXL1, EZH2, IDH1/2, TET2, and DNMT3A have been identified contributing to epigenetic alterations in hematological malignancies 38, 39. This evidence concerns the gene ASXL1 and hematologic disorder.